Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
TheraXyte BioScience is a biotechnology company specializing in extracellular vesicle (EV)-mediated drug delivery and the development of novel therapeutics based on EVs. The company has created an advanced drug delivery platform, known as TAXY, which facilitates the mass production of customizable EVs at a Good Manufacturing Practice (GMP) level. This platform is designed to efficiently package therapeutic payloads and target specific organs or cells, enabling the effective release of drug molecules and biological agents. TheraXyte's mission is to bridge the gap between laboratory research and clinical applications, addressing significant challenges in therapeutic delivery and making a meaningful impact on human health through innovative EV-based solutions.
Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment, particularly targeting solid tumors. The company utilizes advanced technologies, including genome editing, high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical challenges in efficacy and safety, Engimmune aims to provide effective solutions for patients facing serious diseases with significant unmet medical needs. Through its comprehensive platform, the company is dedicated to advancing the next generation of TCR-based therapies, contributing to the evolving landscape of cancer treatment.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Creating novel bispecific antibodies that activate the immune system to fight cancer
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Aristea Therapeutics is a clinical-stage drug development company based in San Diego, California, founded in 2018. The company focuses on creating novel therapies for serious inflammatory diseases and autoimmune conditions. Its research and development efforts are concentrated on addressing unmet medical needs for patients suffering from various conditions, including palmoplantar pustulosis, hidradenitis suppurativa, inflammatory bowel disease, familial Mediterranean fever, and Behçet's disease. By employing a focused and agile approach, Aristea aims to provide innovative treatment options that improve patient outcomes in these challenging therapeutic areas.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.
Altasciences Clinical Research, encompassing Algorithme Pharma, Vince & Associates Clinical Research and Algorithme Pharma USA, is one of the early phase clinical research organizations (CROs) in North America. As a full-service CRO, we have extensive expertise in the execution of a wide range of Phase I/II clinical studies, especially complex trials in healthy normal volunteers and patient populations.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. The company specializes in developing and manufacturing therapies for rare eye diseases, with a particular focus on Stargardt’s disease, a form of juvenile retinal degeneration. Currently operating in stealth mode, Stargazer Pharmaceuticals aims to provide novel treatment options for conditions that lack existing therapies, thus enabling healthcare professionals to better address the needs of patients with these rare diseases.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), a vital enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage of creating a first-in-class series of molecules aimed at reactivating this key tumor suppressor. The firm employs proprietary development tools to facilitate rational drug design, aiming to provide therapeutic solutions for various cancer types and select non-oncology conditions.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Founded in 2014 and based in Daly City, California, the company is primarily focused on its lead candidate, tildacerfont, which is being evaluated in Phase II clinical trials for classic congenital adrenal hyperplasia (CAH) in both adults and children. Tildacerfont aims to be the first non-steroidal treatment that enhances disease control while minimizing the reliance on steroids for managing CAH. Additionally, Spruce Biosciences is exploring tildacerfont's potential applications in treating polycystic ovary syndrome in women. The company has also entered a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications. Through its efforts, Spruce Biosciences seeks to significantly improve the quality of life for patients with rare endocrine disorders who have historically been underserved by medical advancements.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for the treatment of acute and chronic liver diseases. The company’s approach centers on the mitogen-activated protein kinase (MAPK) pathway, specifically targeting MAP kinase kinase 4 (MKK4), a crucial regulator of liver regeneration. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen has demonstrated that small RNA molecules can suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely diseased livers. HepaRegeniX is advancing the development of small-molecule MKK4 inhibitors, which have the potential to address liver disorders, including nonalcoholic steatohepatitis, by enhancing liver regeneration.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Private Equity Round in 2019
WCG is a prominent provider of regulatory and ethical review services for human research, focusing on enhancing the quality and efficiency of clinical studies. The company reviews new research protocols and offers a range of services including clinical and human gene therapy research, laboratory biosafety consulting, and solutions for human research protections. WCG also provides online learning resources, an electronic informed consent solution to streamline clinical processes, oncology review services, and a cloud-based platform for managing research activities. Serving a diverse clientele that includes large pharmaceutical companies, biotechnology firms, and contract research organizations, WCG is committed to accelerating the delivery of new treatments while upholding high standards of human subject protection. Founded in 2012 and headquartered in Princeton, New Jersey, WCG operates multiple locations across the United States and in Tokyo, Japan, and has established a strategic partnership with InformedDNA.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.
Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, specializes in developing peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING pathway, a crucial regulator of innate immunity and tumor development. Stipe Therapeutics has successfully identified and validated compounds that enhance the STING pathway, effectively modulating the tumor microenvironment to promote a strong anti-tumoral response.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative therapies aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology is designed to address a range of autoimmune and allergic diseases, including prevalent conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens, Anokion’s approach provides precise therapies that minimize side effects and enhance patient outcomes in the treatment of autoimmune disorders.
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Aristea Therapeutics is a clinical-stage drug development company based in San Diego, California, founded in 2018. The company focuses on creating novel therapies for serious inflammatory diseases and autoimmune conditions. Its research and development efforts are concentrated on addressing unmet medical needs for patients suffering from various conditions, including palmoplantar pustulosis, hidradenitis suppurativa, inflammatory bowel disease, familial Mediterranean fever, and Behçet's disease. By employing a focused and agile approach, Aristea aims to provide innovative treatment options that improve patient outcomes in these challenging therapeutic areas.
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, founded in 2013. The company specializes in the tissue-specific regulation of sex hormone effects and is focused on developing innovative treatments for urological and endocrinological diseases. Its lead product, Fispemifene, is a selective estrogen receptor modulator designed to address symptoms related to low testosterone in men. Additionally, Forendo is working on a 17HSD1-inhibitor aimed at treating endometriosis. By targeting specific hormone mechanisms, Forendo Pharma seeks to enhance treatment options for both male and female health conditions, addressing unmet medical needs in these areas.
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.
NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at enhancing cancer treatment options. NBE-Therapeutics focuses on creating immune-stimulatory therapies through its proprietary ADC platform, which utilizes a unique anthracycline payload. This innovative approach not only targets tumor cells directly but also aims to induce a durable immunological response against tumors. By developing these advanced therapies, NBE-Therapeutics seeks to improve survival rates and enhance the quality of life for cancer patients globally.
Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.
Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for the treatment of acute and chronic liver diseases. The company’s approach centers on the mitogen-activated protein kinase (MAPK) pathway, specifically targeting MAP kinase kinase 4 (MKK4), a crucial regulator of liver regeneration. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen has demonstrated that small RNA molecules can suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely diseased livers. HepaRegeniX is advancing the development of small-molecule MKK4 inhibitors, which have the potential to address liver disorders, including nonalcoholic steatohepatitis, by enhancing liver regeneration.
Hoba Therapeutics
Seed Round in 2016
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Arch Oncology is an immuno-oncology company focused on developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Founded in 2006 and based in St. Louis, Missouri, with a corporate office in Brisbane, California, the company aims to create innovative therapies that leverage both adaptive and innate immune responses. Arch Oncology's approach involves a new class of checkpoint inhibitors, which represents a significant advancement in cancer treatment. Through its research and development efforts, the company seeks to improve outcomes for patients battling various forms of cancer.